Congenital Hyperinsulinism Market - Global Outlook and Forecast 2021-2027

April 2021 | 92 pages | ID: C2239BAD6A9EEN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Congenital Hyperinsulinism in Global, including the following market information:

Global Congenital Hyperinsulinism Market Revenue, 2016-2021, 2022-2027, ($ millions)

Global top five companies in 2020 (%)

The global Congenital Hyperinsulinism market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Congenital Hyperinsulinism companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Congenital Hyperinsulinism Market, By Type, 2016-2021, 2022-2027 ($ millions)

Global Congenital Hyperinsulinism Market Segment Percentages, By Type, 2020 (%)

• Surgery
• Medication
• Others

China Congenital Hyperinsulinism Market, By Application, 2016-2021, 2022-2027 ($ millions)

China Congenital Hyperinsulinism Market Segment Percentages, By Application, 2020 (%)

• Hospital
• Clinic
• Others

Global Congenital Hyperinsulinism Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)

Global Congenital Hyperinsulinism Market Segment Percentages, By Region and Country, 2020 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Total Congenital Hyperinsulinism Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)

Total Congenital Hyperinsulinism Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:

• IVAX Pharmaceuticals
• Teva Pharmaceuticals
• Zealand Pharma
• Rezolute
• Xeris Pharmaceuticals
• Eiger BioPharmaceuticals
• AmideBio
• Recordati

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Hereditary Transthyretin Amyloidosis (HATTR) Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL HEREDITARY TRANSTHYRETIN AMYLOIDOSIS (HATTR) OVERALL MARKET SIZE

2.1 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size: 2021 VS 2027
2.2 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Hereditary Transthyretin Amyloidosis (HATTR) Players in Global Market
3.2 Top Global Hereditary Transthyretin Amyloidosis (HATTR) Companies Ranked by Revenue
3.3 Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue by Companies
3.4 Top 3 and Top 5 Hereditary Transthyretin Amyloidosis (HATTR) Companies in Global Market, by Revenue in 2020
3.5 Global Companies Hereditary Transthyretin Amyloidosis (HATTR) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Hereditary Transthyretin Amyloidosis (HATTR) Players in Global Market
  3.6.1 List of Global Tier 1 Hereditary Transthyretin Amyloidosis (HATTR) Companies
  3.6.2 List of Global Tier 2 and Tier 3 Hereditary Transthyretin Amyloidosis (HATTR) Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size Markets, 2021 & 2027
  4.1.2 Oral
  4.1.3 Subcutaneous Injection
  4.1.4 Others
4.2 By Type - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue & Forecasts
  4.2.1 By Type - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2016-2021
  4.2.2 By Type - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2022-2027
  4.2.3 By Type - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue Market Share, 2016-2027

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2021 & 2027
  5.1.2 Hospital
  5.1.3 Clinic
  5.1.4 Others
5.2 By Application - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue & Forecasts
  5.2.1 By Application - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2016-2021
  5.2.2 By Application - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2022-2027
  5.2.3 By Application - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue Market Share, 2016-2027

6 SIGHTS BY REGION

6.1 By Region - Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2021 & 2027
6.2 By Region - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue & Forecasts
  6.2.1 By Region - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2016-2021
  6.2.2 By Region - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2022-2027
  6.2.3 By Region - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue Market Share, 2016-2027
6.3 North America
  6.3.1 By Country - North America Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2016-2027
  6.3.2 US Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027
  6.3.3 Canada Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027
  6.3.4 Mexico Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027
6.4 Europe
  6.4.1 By Country - Europe Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2016-2027
  6.4.2 Germany Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027
  6.4.3 France Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027
  6.4.4 U.K. Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027
  6.4.5 Italy Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027
  6.4.6 Russia Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027
  6.4.7 Nordic Countries Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027
  6.4.8 Benelux Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027
6.5 Asia
  6.5.1 By Region - Asia Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2016-2027
  6.5.2 China Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027
  6.5.3 Japan Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027
  6.5.4 South Korea Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027
  6.5.5 Southeast Asia Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027
  6.5.6 India Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027
6.6 South America
  6.6.1 By Country - South America Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2016-2027
  6.6.2 Brazil Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027
  6.6.3 Argentina Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2016-2027
  6.7.2 Turkey Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027
  6.7.3 Israel Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027
  6.7.4 Saudi Arabia Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027
  6.7.5 UAE Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2016-2027

7 PLAYERS PROFILES

7.1 Pfizer
  7.1.1 Pfizer Corporate Summary
  7.1.2 Pfizer Business Overview
  7.1.3 Pfizer Hereditary Transthyretin Amyloidosis (HATTR) Major Product Offerings
  7.1.4 Pfizer Hereditary Transthyretin Amyloidosis (HATTR) Revenue in Global (2016-2021)
  7.1.5 Pfizer Key News
7.2 Alnylam Pharmaceuticals
  7.2.1 Alnylam Pharmaceuticals Corporate Summary
  7.2.2 Alnylam Pharmaceuticals Business Overview
  7.2.3 Alnylam Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Major Product Offerings
  7.2.4 Alnylam Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Revenue in Global (2016-2021)
  7.2.5 Alnylam Pharmaceuticals Key News
7.3 Akcea Therapeutics
  7.3.1 Akcea Therapeutics Corporate Summary
  7.3.2 Akcea Therapeutics Business Overview
  7.3.3 Akcea Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Major Product Offerings
  7.3.4 Akcea Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Revenue in Global (2016-2021)
  7.3.5 Akcea Therapeutics Key News
7.4 Prothena
  7.4.1 Prothena Corporate Summary
  7.4.2 Prothena Business Overview
  7.4.3 Prothena Hereditary Transthyretin Amyloidosis (HATTR) Major Product Offerings
  7.4.4 Prothena Hereditary Transthyretin Amyloidosis (HATTR) Revenue in Global (2016-2021)
  7.4.5 Prothena Key News
7.5 Lonis Pharmaceuticals
  7.5.1 Lonis Pharmaceuticals Corporate Summary
  7.5.2 Lonis Pharmaceuticals Business Overview
  7.5.3 Lonis Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Major Product Offerings
  7.5.4 Lonis Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Revenue in Global (2016-2021)
  7.5.5 Lonis Pharmaceuticals Key News
7.6 Eidos Therapeutics
  7.6.1 Eidos Therapeutics Corporate Summary
  7.6.2 Eidos Therapeutics Business Overview
  7.6.3 Eidos Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Major Product Offerings
  7.6.4 Eidos Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Revenue in Global (2016-2021)
  7.6.5 Eidos Therapeutics Key News
7.7 Corino Therapeutics Inc
  7.7.1 Corino Therapeutics Inc Corporate Summary
  7.7.2 Corino Therapeutics Inc Business Overview
  7.7.3 Corino Therapeutics Inc Hereditary Transthyretin Amyloidosis (HATTR) Major Product Offerings
  7.4.4 Corino Therapeutics Inc Hereditary Transthyretin Amyloidosis (HATTR) Revenue in Global (2016-2021)
  7.7.5 Corino Therapeutics Inc Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Congenital Hyperinsulinism Market Opportunities & Trends in Global Market
Table 2. Congenital Hyperinsulinism Market Drivers in Global Market
Table 3. Congenital Hyperinsulinism Market Restraints in Global Market
Table 4. Key Players of Congenital Hyperinsulinism in Global Market
Table 5. Top Congenital Hyperinsulinism Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Congenital Hyperinsulinism Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Congenital Hyperinsulinism Revenue Share by Companies, 2016-2021
Table 8. Global Companies Congenital Hyperinsulinism Product Type
Table 9. List of Global Tier 1 Congenital Hyperinsulinism Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Congenital Hyperinsulinism Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type – Global Congenital Hyperinsulinism Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - Congenital Hyperinsulinism Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - Congenital Hyperinsulinism Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application – Global Congenital Hyperinsulinism Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - Congenital Hyperinsulinism Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - Congenital Hyperinsulinism Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region – Global Congenital Hyperinsulinism Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global Congenital Hyperinsulinism Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global Congenital Hyperinsulinism Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America Congenital Hyperinsulinism Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe Congenital Hyperinsulinism Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia Congenital Hyperinsulinism Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America Congenital Hyperinsulinism Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa Congenital Hyperinsulinism Revenue, (US$, Mn), 2022-2027
Table 30. IVAX Pharmaceuticals Corporate Summary
Table 31. IVAX Pharmaceuticals Congenital Hyperinsulinism Product Offerings
Table 32. IVAX Pharmaceuticals Congenital Hyperinsulinism Revenue (US$, Mn), (2016-2021)
Table 33. Teva Pharmaceuticals Corporate Summary
Table 34. Teva Pharmaceuticals Congenital Hyperinsulinism Product Offerings
Table 35. Teva Pharmaceuticals Congenital Hyperinsulinism Revenue (US$, Mn), (2016-2021)
Table 36. Zealand Pharma Corporate Summary
Table 37. Zealand Pharma Congenital Hyperinsulinism Product Offerings
Table 38. Zealand Pharma Congenital Hyperinsulinism Revenue (US$, Mn), (2016-2021)
Table 39. Rezolute Corporate Summary
Table 40. Rezolute Congenital Hyperinsulinism Product Offerings
Table 41. Rezolute Congenital Hyperinsulinism Revenue (US$, Mn), (2016-2021)
Table 42. Xeris Pharmaceuticals Corporate Summary
Table 43. Xeris Pharmaceuticals Congenital Hyperinsulinism Product Offerings
Table 44. Xeris Pharmaceuticals Congenital Hyperinsulinism Revenue (US$, Mn), (2016-2021)
Table 45. Eiger BioPharmaceuticals Corporate Summary
Table 46. Eiger BioPharmaceuticals Congenital Hyperinsulinism Product Offerings
Table 47. Eiger BioPharmaceuticals Congenital Hyperinsulinism Revenue (US$, Mn), (2016-2021)
Table 48. AmideBio Corporate Summary
Table 49. AmideBio Congenital Hyperinsulinism Product Offerings
Table 50. AmideBio Congenital Hyperinsulinism Revenue (US$, Mn), (2016-2021)
Table 51. Recordati Corporate Summary
Table 52. Recordati Congenital Hyperinsulinism Product Offerings
Table 53. Recordati Congenital Hyperinsulinism Revenue (US$, Mn), (2016-2021)

List Of Figures

LIST OF FIGURES

Figure 1. Congenital Hyperinsulinism Segment by Type
Figure 2. Congenital Hyperinsulinism Segment by Application
Figure 3. Global Congenital Hyperinsulinism Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Congenital Hyperinsulinism Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global Congenital Hyperinsulinism Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Congenital Hyperinsulinism Revenue in 2020
Figure 8. By Type - Global Congenital Hyperinsulinism Revenue Market Share, 2016-2027
Figure 9. By Application - Global Congenital Hyperinsulinism Revenue Market Share, 2016-2027
Figure 10. By Region - Global Congenital Hyperinsulinism Revenue Market Share, 2016-2027
Figure 11. By Country - North America Congenital Hyperinsulinism Revenue Market Share, 2016-2027
Figure 12. US Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 13. Canada Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe Congenital Hyperinsulinism Revenue Market Share, 2016-2027
Figure 16. Germany Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 17. France Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 19. Italy Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 20. Russia Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia Congenital Hyperinsulinism Revenue Market Share, 2016-2027
Figure 24. China Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 25. Japan Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 28. India Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America Congenital Hyperinsulinism Revenue Market Share, 2016-2027
Figure 30. Brazil Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa Congenital Hyperinsulinism Revenue Market Share, 2016-2027
Figure 33. Turkey Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 34. Israel Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 36. UAE Congenital Hyperinsulinism Revenue, (US$, Mn), 2016-2027
Figure 37. IVAX Pharmaceuticals Congenital Hyperinsulinism Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Teva Pharmaceuticals Congenital Hyperinsulinism Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. Zealand Pharma Congenital Hyperinsulinism Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. Rezolute Congenital Hyperinsulinism Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. Xeris Pharmaceuticals Congenital Hyperinsulinism Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. Eiger BioPharmaceuticals Congenital Hyperinsulinism Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 43. AmideBio Congenital Hyperinsulinism Revenue Year Over Year Growth (US$, Mn) & (2016-2021)